Healthy adult
Conditions
Interventions
Application of the lotion 1 to the target skin area twice a day (morning and night) for 1 week before UV irradiation and 4 weeks after irradiation.
Application of the lotion 2 to the target skin area
Sponsors
Otsuka Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Subjects whose age at consent day is from 30 to 60 years old 2)Subjects with Fitzpatrick skin type II or III 3)Subjects who are judged to be suitable for this study from the pre-application check by the principle investigator 4)Subjects who are voluntary participation and informed consent
Exclusion criteria
Exclusion criteria: 1)Subjects with photosensitive skin. 2)Subjects who have significant change of skin condition by menstrual cycle. 3)Subjects who take drugs that affect skin photosensitivity. 4)Subjects who have the factors on the target area which may affect this study. 5)Subjects who have got aesthetic medicine on the target area. 6)Subjects who continuously use skin care products or functional foods on the target area which had same or similar effect with the test sample. 7)Subjects who continuously use bath additive, excluding one who can stop using them during this study. 8)Subjects who continuously use moisturizer and/or body cream on the target area, excluding one who can stop using them during this study. 9)Subjects who continuously use drugs which have effect on pigmentation and/or melasma. 10)Subjects with atopic dermatitis, regardless of the area. 11)Subjects who have undergone special skincare treatment at the target area within 4 weeks or during this study. 12)Subjects who have changed and/or started using functional foods and/or sunscreen on the target area within 4 weeks. 13)Subjects who have or will be exposed to excessive UV beyond the daily life during this study. 14)Subjects who are night or shift workers. 15)Subjects who have treated or prevented their disease or need to be treatment in a clinic at the consent 16)Subjects who have serious diseases or medical history including glucose or lipid metabolisms, liver or kidney functions, cardiovascular, respiratory, endocrine or nervous systems. 17)Subjects with a history of alcohol and/or drug addiction. 18)Subjects who have a risk of allergy during this study. 19)Subjects who are pregnant, lactating or hoping to be pregnant during this study. 20)Subjects who participated in the similar study within 6 months. 21)Subjects who have participated or will participate in the other clinical study within 4 weeks. 22)Subjects who are judged as ineligible for participating in this study by the principle investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin color (L*, a*, b*), melanin index, erythema index on the target skin area at 0, 1 days and 3, 4 weeks. | — |
Countries
Japan
Contacts
Public ContactSachiyo Igarashi
Otsuka Pharmaceutical Co., Ltd. Otsu Skin Care Research Institute
Outcome results
None listed